Literature DB >> 8822532

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.

M E Stockton1, K Rasmussen.   

Abstract

This study examined the effects of the novel atypical antipsychotic olanzapine (LY170053) on the activity of substantia nigra pars compacta (A9) and ventral tegmental area (A10) dopamine cells in anesthetized rats. Acute administration of olanzapine (10, 20 mg/kg sc) increased the number of spontaneously active A10, but not A9, dopamine cells. Chronic administration of olanzapine (10, 20 mg/kg/day x 21 days) decreased the number of spontaneously active A10, but not A9, dopamine cells. Administration of the dopamine agonist apomorphine reversed the effects of chronic olanzapine on A10 cells, indicating a possible depolarization-inactivation mechanism. In conclusion, olanzapine has selective effects on A10 versus A9 dopamine cells following acute and chronic administration. These effects of olanzapine on dopamine cells are similar to the effects observed with clozapine and may play an important role in the atypical antipsychotic profile of olanzapine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822532     DOI: 10.1016/0893-133X(94)00130-R

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  22 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

3.  Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.

Authors:  C M Beasley; T Sanger; W Satterlee; G Tollefson; P Tran; S Hamilton
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Authors:  F P Bymaster; S K Hemrick-Luecke; K W Perry; R W Fuller
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Spotlight on olanzapine in bipolar I disorder.

Authors:  Paul L McCormack; Lynda R Wiseman
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 8.  Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations.

Authors:  C C Abbott; A Jaramillo; C E Wilcox; D A Hamilton
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 9.  Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.

Authors:  Rae Price; Bahar Salavati; Ariel Graff-Guerrero; Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis; Tarek K Rajji
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-05-10       Impact factor: 5.067

10.  Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method.

Authors:  Atheir I Abbas; Daniel J Urban; Niels H Jensen; Martilias S Farrell; Wesley K Kroeze; Piotr Mieczkowski; Zefeng Wang; Bryan L Roth
Journal:  Nucleic Acids Res       Date:  2010-02-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.